About project
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children and has a favorable prognosis for long-term survival.
The poorest treatment outcomes for this disease occur in patients with a congenital predisposition to cancer, who often present an increased risk of severe, life-threatening toxicity from therapy as well as an increased likelihood of developing a secondary malignancy.
This group requires personalized ALL treatment in a new protocol to reduce the risk of adverse events (including late complications of therapy) and improve survival.
The proposed project is an attempt to address these needs by developing diagnostic and therapeutic solutions based on the integration of genotypic data (derived from genome-wide profiling of constitutional variants) with the clinical course of leukemia, in the context of treatment response and complications.
Specific objective
